<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468272</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1103-PR-0058</org_study_id>
    <nct_id>NCT01468272</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years Old</brief_title>
  <acronym>PAED4</acronym>
  <official_title>A Single-dose,Open-label,Randomized,2-way Cross-over,Clinical Pharmacology Study of CHF1535 50/6 NEXT DPI® Fixed Combination of Beclomethasone Dipropionate 50µg Plus Formoterol Fumarate 6µg)Versus the Free Combination of Licensed Beclomethasone DPI and Formoterol DPI in Asthmatic Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pharmacokinetic comparison of CHF 1535 50/6 NEXT DPI versus the free combination of
      Beclomethasone DPI and Formoterol DPI in children (5 to 11 years old) of a formulation
      already approved in adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetic study in asthmatic children 5 to 11 years old treated with either a fixed
      combination of beclomethasone 50 ug/unit dose plus formoterol fumarate 6 ug/unit dose via the
      NEXT DPI dry powder inhaler or a free combination of Beclomethasone 100 ug DPI and Formoterol
      6 ug DPI according to a cross-over design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>B17MP (active metabolite of BDP) Area Under Curve (AUC)</measure>
    <time_frame>predose, 15,30min, 1,2,4,6,8 hours post dose</time_frame>
    <description>B17MP: Profile of Pharmacokinetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>B17MP Cmax,Tmax,T1/2</measure>
    <time_frame>predose, 15min,30min,1,2,4,6,8 hours post dose</time_frame>
    <description>BDP: profile of pharmacokinetics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDP Area Under Curve (AUC), Cmax, Tmax, T1/2</measure>
    <time_frame>predose, 15min,30min,1,2,4,6,8 hours postdose</time_frame>
    <description>BDP: profile of Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formoterol Area Under Curve (AUC), Cmax, Tmax, T1/2</measure>
    <time_frame>predose, 15min, 30 min, 1,2,4,6,8 hours postdose</time_frame>
    <description>Formoterol: profile of pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma potassium Area Under Curve (AUC), Cmin, Tmin</measure>
    <time_frame>predose, 15min, 30min, 1, 2, 4, 6, 8 hours postdose</time_frame>
    <description>plasma potassium to evaluate drug systemic effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate: Time averaged Heart Rate value: AUC0-t/t</measure>
    <time_frame>predose, 15min, 30min, 1, 2, 4, 6, 8 hours postdose</time_frame>
    <description>Heart Rate to evaluate drug systemic effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Cortisol: Amount excreted in 0-8hours (Ae),8h cortisol urinary excretion normalized for 8h creatinine excretion (Ae/Aecreat).</measure>
    <time_frame>from predose up to 8 hours postdose</time_frame>
    <description>Urinary cortisol to evaluate drug systemic effect</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Asthma in Children</condition>
  <arm_group>
    <arm_group_label>reference treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Free combination of Beclomethasone dipropionate DPI and Formoterol fumarate DPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 1535 NEXT DPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 1535 50/6 NEXT DPI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>free comb. beclomethasone DPI and formoterol DPI</intervention_name>
    <description>free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).</description>
    <arm_group_label>reference treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 50/6 NEXT DPI</intervention_name>
    <description>four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)</description>
    <arm_group_label>CHF 1535 NEXT DPI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male/Female children aged 5 -11y

          2. Written informed consent obtained by parents/legal representative (according to local
             regulation) and by the minor (age and local regulation permitting).

          3. Children with stable asthma

          4. Children with asthma on regular treatment with ICS or using short-acting inhaled
             beta2-agonists as reliever to control asthma symptoms

          5. Forced expiratory volume in one second (FEV1) &gt; 70% of predicted values (% pred) after
             withholding beta2-agonists treatment for a minimum of 4 h prior to each study
             treatment.

          6. A cooperative attitude and ability to be trained about the proper use of DPI and
             compliant to study procedures.

        Exclusion Criteria:

          1. Past or present diagnoses of cardiovascular, renal or liver disease

          2. Known hypersensitivity to the active treatments

          3. Exacerbation of asthma symptoms within the previous 4 weeks

          4. Inability to perform the required breathing technique and blood sampling

          5. Hospitalization due to exacerbation of asthma within 1 month prior to screening (visit
             1)

          6. Lower respiratory tract infection within 1 month prior to screening (visit 1)

          7. Disease (other than asthma) which might influence the outcome of the study

          8. Obesity, i.e. &gt; 97% weight percentile by local standards
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Bisgaard</last_name>
    <role>Principal Investigator</role>
    <affiliation>BorneAstmaKlinikken, Copenaghen, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BørneAstmaKlinikken, Hans Knudsens Plads 1A,</name>
      <address>
        <city>Copenhagen,</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001208-36</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma children NEXT DPI LABA ICS inhalation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

